Andrea Tan
Stock Analyst at Goldman Sachs
(1.92)
# 1,707
Out of 4,412 analysts
28
Total ratings
32%
Success rate
-3.41%
Average return
Main Sectors:
Top Industries:
13 Stocks
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SGMT Sagimet Biosciences | Maintains: Buy | $37 → $27 | $4.06 | +565.02% | 3 | Mar 26, 2024 | |
| IOVA Iovance Biotherapeutics | Maintains: Buy | $19 → $21 | $11.64 | +80.41% | 4 | Feb 29, 2024 | |
| TARS Tarsus Pharmaceuticals | Maintains: Neutral | $19 → $30 | $32.04 | -6.37% | 2 | Feb 29, 2024 | |
| DAWN Day One Biopharmaceuticals | Maintains: Buy | $50 → $44 | $14.92 | +194.91% | 4 | Feb 27, 2024 | |
| KOD Kodiak Sciences | Reinstates: Sell | $2 | $3.28 | -39.02% | 1 | Dec 11, 2023 | |
| KRYS Krystal Biotech | Initiates: Buy | $160 | $156.88 | +1.99% | 1 | Nov 20, 2023 | |
| ABCL AbCellera Biologics | Maintains: Buy | $27 → $24 | $3.76 | +538.30% | 2 | Aug 4, 2023 | |
| INSM Insmed | Maintains: Buy | $44 → $39 | $24.80 | +57.26% | 3 | Jan 9, 2023 | |
| FATE Fate Therapeutics | Maintains: Sell | $10 → $4 | $3.80 | +5.26% | 2 | Jan 9, 2023 | |
| MDGL Madrigal Pharmaceuticals | Maintains: Buy | $178 → $375 | $193.33 | +93.97% | 1 | Dec 20, 2022 | |
| VERV Verve Therapeutics | Initiates: Sell | $13 | $6.16 | +111.04% | 1 | Dec 15, 2022 | |
| RLMD Relmada Therapeutics | Downgrades: Neutral | $8 | $3.83 | +108.88% | 2 | Oct 14, 2022 | |
| VOR Vor Biopharma | Maintains: Neutral | $6 → $4 | $1.69 | +136.69% | 2 | May 24, 2022 |
Sagimet Biosciences
Mar 26, 2024
Maintains: Buy
Price Target: $37 → $27
Current: $4.06
Upside: +565.02%
Iovance Biotherapeutics
Feb 29, 2024
Maintains: Buy
Price Target: $19 → $21
Current: $11.64
Upside: +80.41%
Tarsus Pharmaceuticals
Feb 29, 2024
Maintains: Neutral
Price Target: $19 → $30
Current: $32.04
Upside: -6.37%
Day One Biopharmaceuticals
Feb 27, 2024
Maintains: Buy
Price Target: $50 → $44
Current: $14.92
Upside: +194.91%
Kodiak Sciences
Dec 11, 2023
Reinstates: Sell
Price Target: $2
Current: $3.28
Upside: -39.02%
Krystal Biotech
Nov 20, 2023
Initiates: Buy
Price Target: $160
Current: $156.88
Upside: +1.99%
AbCellera Biologics
Aug 4, 2023
Maintains: Buy
Price Target: $27 → $24
Current: $3.76
Upside: +538.30%
Insmed
Jan 9, 2023
Maintains: Buy
Price Target: $44 → $39
Current: $24.80
Upside: +57.26%
Fate Therapeutics
Jan 9, 2023
Maintains: Sell
Price Target: $10 → $4
Current: $3.80
Upside: +5.26%
Madrigal Pharmaceuticals
Dec 20, 2022
Maintains: Buy
Price Target: $178 → $375
Current: $193.33
Upside: +93.97%
Verve Therapeutics
Dec 15, 2022
Initiates: Sell
Price Target: $13
Current: $6.16
Upside: +111.04%
Relmada Therapeutics
Oct 14, 2022
Downgrades: Neutral
Price Target: $8
Current: $3.83
Upside: +108.88%
Vor Biopharma
May 24, 2022
Maintains: Neutral
Price Target: $6 → $4
Current: $1.69
Upside: +136.69%